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Abstract
Background: Hormonally-regulated histone modifications that govern positive versus negative transcription of target genes
are poorly characterized despite their importance for normal and pathological endocrine function. There have been only a
few studies examining chromatin modifications on target gene promoters by nuclear hormone receptors. Moreover, these
studies have focused on positively-regulated target genes. TSHa, a heterodimer partner for thyrotropin (TSH), is secreted by
the pituitary gland. T3 negatively regulates TSHa gene expression via thyroid hormone receptors (TRs) which belong to the
nuclear hormone receptor superfamily, whereas thyrotropin releasing hormone (TRH) positively regulates via the TRH
receptor, a G protein-coupled receptor.
Methodology/Principal Findings: We studied regulation of the TSHa gene by cAMP and T3 using chromatin
immunoprecipitation (ChIP) assays in stably-transfected rat pituitary cells containing the human TSHa promoter.
Interestingly, cAMP selectively increased histone H4 acetylation whereas, as previously reported, T3 induced histone H3
acetylation. In particular, cAMP increased H4K5 and H4K8 acetylation and decreased H4K20 trimethylation, modifications
associated with transcriptional activation. T3 increased H3K9 and H3K18 acetylation and H3K4 trimethylation; however, it
also decreased H3K27 acetylation and increased H3K27 trimethylation which are associated with transcriptional repression.
Of note, cAMP recruited pCREB, CBP/p300, and PCAF to the promoter whereas T3 caused dissociation of NCoR/SMRT and
HDAC3. Overexpression of a dominant negative mutant thyroid hormone receptor (TR) from a patient with resistance to
thyroid hormone (RTH) led to less T3-dependent negative regulation and partially blocked histone H3 modifications of the
TSHa promoter.
Conclusions/Significance: Our findings show that non-overlapping and specific histone modifications determine positive
versus negative transcriptional regulation, and integrate opposing hormonal and intracellular signals at the TSHa promoter.
A mutant TR from a patient with RTH exerted dominant negative activity by blocking the histone modifications induced by
T3 on the TSHa promoter and likely contributes to the inappropriate TSH production observed in RTH.
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Introduction
Thyroid hormone receptors (TRs) are members of the nuclear
hormone receptor superfamily that are responsible for many of the
physiological and cellular effects by thyroid hormones. Moreover,
in response to triiodothyronine (T3), TRs mediate positive and
negative transcription of target genes [1,2]. In positively-regulated
target genes, unliganded TRs bind to thyroid hormone response
elements (TREs) in the promoters of target genes. They also
associate with corepressors such as nuclear receptor corepressor
(NCoR) or silencing mediator for retinoic and thyroid hormone
receptors (SMRT) in corepressor complexes also containing
transducin b-like protein 1 (TBL1) and histone deacetylase 3
(HDAC3). These complexes cause histone deacetylation of the
promoter region near the TRE, heterochromatin formation, and
transcriptional repression [3–5]. When T3 is present, corepressor
complexes dissociate from liganded TRs whereas coactivator
complexes that contain steroid receptor coactivator (SRCs), CBP,
and P/CAF bind to TRs. These coactivator complexes contain
histone acetyltransferase (HAT) activity and induce histone
acetylation near the TREs of target genes [6–8]. Additionally,
histone demethylation also occurs on some nuclear receptor target
genes, particularly H3K4 and H3K9 [9–12]. ATP-dependent
chromatin remodeling complexes similar to yeast SWI/SNF which
contain the ATPase subunit, Brahma-related gene (BRG1) also are
recruited to the promoter [13,14] and likely facilitate chromatin
renodeling necessary for HAT activity by SRC complexes and
demethylases. Another major complex, Mediator, interacts with
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transcriptional start site [6,15,16].
Despite evidence that the majority of target genes appear to be
negatively-regulated by T3 [17], the mechanism(s) for negative
transcriptional regulation is not well understood. For several
negatively-regulated genes, NCoR and SMRT increase basal
transcription of target genes in the absence of T3 [18–21].
Coactivators also may be involved in T3-dependent negative
regulation [22]. For the TSHa gene, we recently showed that a
corepressor complex containing NcoR/SMRT, TBL1, and
HDAC3 binds to the promoter of the TSHa gene and mediates
basal transcription in the absence of T3 [23]. However, when T3 is
present, this corepressor complex is released from TR, which, in
turn, leads to increased histone acetylation and negative regulation
of the TSHa gene expression [23]. These unexpected results
demonstrate that histone acetylation per se does not universally
lead to transcriptional activation.
Previous studies have shown that the hypothalamic tripeptide,
thyrotropin releasing hormone (TRH), stimulates adenyl cyclase
activity and induces cAMP production leading to increased TSHa
gene expression [24]. The TSHa gene promoter has two cAMP
response elements (CREs) [19] and dibutyryl cAMP also can
activate TSHa gene transcription [22]. We previously generated a
permanently-transfected rat pituitary cell line (a-23) that contains
luciferase cDNA under the control of the human TSHa promoter
(2846 to +1) [23]. This portion of the promoter contains the two
CREs and is negatively regulated by T3. In this manuscript, we
examine the transcriptional mechanisms and histone modifications
of cAMP and T3 on the TSHa gene promoter. Our findings show
that although common general mechanisms may be utilized for
positive and negative regulation, in a given target gene such as
TSHa, different co-factors as well as histone modifications at
distinct sites, may determine positive versus negative regulation of
transcription. Moreover, the particular constellation of histone
modifications at the promoter may enable integration of opposing
hormonal and intracellular signals at the target gene promoter.
Last, we show that in the genetic syndrome of RTH, disruption of
T3-dependent histone modifications by a dominant negative
mutant TR may lead to inappropriate TSHa secretion.
Results
We previously generated a permanently-transfected pituitary
cell line (a223 cells) which incorporated a human TSHa
promoter/luciferase cDNA construct (Figure 1) that was nega-
tively-regulated by T3 [23]. This line was generated from
somatrope/lactotrope GH3 cells since there are no readily-
cultured pituitary cell lines which express TSHa that can be
negatively-regulated by T3. Additionally, no significant amounts of
endogenous TSHa mRNA could not be detected by quantitative
RT-PCR and microarray analyses (data not shown).
We examined the transcriptional activity of human TSHa
promoter in a223 cells by measuring luciferase activity and
mRNA expression by quantitative RT-PCR (Figure 2A, B).
Negative regulation of transcription by T3 and positive regulation
by cAMP were seen as early as one hour. Negative regulation also
was observed in cells treated with both T3 and cAMP; however,
the level of transcription was higher than T3 alone. The mean fold-
change in transcription observed in cells treated with cAMP vs.
cAMP + T3, was similar to control vs,T 3 alone (3.6 +/2 0.5 s.d. vs.
3.9 +/2 0.4 s.d., respectively).
We next used ChIP assay to examine the acetylation of histones
H3 (H3) and H4 (H4) under all four conditions (Figure 2C,D). The
integrated human TSHa promoter region could be distinguished
from the endogenous rat TSHa promoter due to specific
amplification using a downstream luciferase cDNA primer in
ChIP assays. In the control cells, there was a moderate amount of
H4 acetylation and no detectable H3 acetylation. As we recently
reported [23], there was increased H3 acetylation without any
change in overall H4 acetylation in the presence of T3. When cells
were treated with cAMP, there was an increase in H4 acetylation
without any measurable H3 acetylation. When cells were treated
with T3 and cAMP, both H3 acetylation and increased H4
acetylation occurred. Taken together, these findings suggest that
H3 acetylation occurs with T3 treatment whereas increased H4
acetylation occurs with cAMP treatment.
In order to examine the co-factors that may be involved in these
changes in histone acetylation, we performed ChIP assays to
examine co-factors bound to the TSHa promoter under all four
conditions (Figure 3A, B). As reported previously, T3 caused
decreased NCoR, SMRT, and HDAC3 binding to the promoter
but did not affect TR binding [23]. cAMP alone did not change
binding of these co-factors; however, concomitant addition of T3
decreased their binding. These findings suggest that loss of the
NCoR/SMRT/HDAC3 complex binding is likely a major
contributor to the negative regulation of TSHa gene by T3 even
in the presence of cAMP. In contrast, pCREB, CBP, p300, and
PCAF all increased their binding to the TSHa promoter after
cAMP treatment; however, their binding to the TSHa promoter
was unaffected by T3. These latter findings suggest that
recruitment of this HAT complex likely causes the increased H4
acetylation on the TSHa promoter observed with cAMP
treatment.
We next examined acetylation of specific H3 sites under the same
four conditions (Figure 4A, B). T3 increased H3K9 and H3K18
acetylation and decreased H3K27 acetylation. These findings suggest
that although T3 induced an overall increase in H3 acetylation, it also
decreased histone acetylation at H3K27. We then examined
Figure 1. Diagram of TSHa promoter and location of primers in ChIP assays. Shown is the promoter region and luciferase cDNA. The
upstream primer started at 2324 bp and the downstream primer started at +23 bp from transcriptional start site of luciferase gene. Primers denoted
by arrows. CRE-cyclic AMP response element; TATA-TATA box.
doi:10.1371/journal.pone.0009853.g001
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changes when compared to acetylation at these sites as T3 decreased
H3K9, and increased H3K27 trimethylation. H3K4 methylation,
which usually is associated with increased transcriptional activity [25],
also was increased by T3. cAMP did not alter modifications on any of
the foregoing H3 sites in the absence or presence of T3.T a k e n
together, these data further confirm our previous findings [23] that T3
preferentially modulates H3 acetylation and methylation of the
hTSHa promoter in our system.
We then examined histone modifications at specific H4 sites
(Figure 5A, B) under the same conditions. T3 did not change the
acetylation or methylation on any of the H4 sites examined. In
contrast, cAMP increased H4K5 and H4K8 acetylation without
affecting H4K16 acetylation. It also decreased H4K20 trimethyla-
tion, which has been associated with transcriptional repression
[25,26]. Given the lack of any changes observed on H3, these
findings suggest that cAMP caused both site-specific and histone-
specific modifications on H4. H3S10 phosphorylation also has
been associated with transcriptional activation [10]; however, we
did not observe any phosphorylation changes at this site with
either T3 or cAMP treatment (data not shown).
Resistance to thyroid hormone (RTH) is a clinical syndrome in
which most affected patients have a mutant TRb allele that encodes
a mutant receptor which has decreased binding affinity for T3
leading to decreased transcriptional activity [27]. The mutant
receptor can still bind to TREs of target genes resulting in dominant
negative activity on the transcription by the wild-type TRs, most
likely due to competition with the latter for binding to TREs. To
better understand the mechanism of the dominant negative activity
on the negative regulation of TSHa gene expression, we examined
the effects of a mutant TR (Mf-1) from a RTH patient [28], on
histone modifications of the TSHa promoter in the absence or
presence of T3 using adenovirus-GFP control as well as adenovirus
encoding wild-type TRb or Mf-1 in a-23 cells (Figure 6A). In cells
transformed with adenovirus control and adenovirus TRb,
luciferase mRNA expression decreased to similar levels 1 hour
after treatment with T3. In contrast, luciferase mRNA expression
remained essentially unchanged after T3 treatment in cells
transformed with adenovirus Mf-1. The protein expression of
wild-type TRb and Mf-1 in transformed cells was confirmed by
Western blotting (data not shown). We next examined H3
modifications that were induced by T3 (Figure 6B), Mf-1 partially
blocked the increases in H3K9 and H3K18 acetylation, and the
decrease in H3K27 acetylation. It also blocked the T3-induced
decrease in H3K9 methylation and increases in H3K27 and H3K4
methylation. These findings suggest that Mf-1 exerts its dominant
negative activity by blocking all of the observed T3-induced H3
modifications of the TSHa promoter.
Discussion
Our studies examined the histone modifications involved in
negative and positive regulation of TSHa by T3 and cAMP,
respectively. Several conclusions can be drawn from our current
and previous findings [23]. First, histone acetylation can occur
during both negative and positive regulation of the same target
gene, as the chromatin changes induced by T3 and cAMP lead to
opposite effects on transcriptional activity and recruitment of RNA
pol II [23] (Figure 3), respectively, on the TSHa promoter.
Second, NCoR/HDAC3 complex appears to determine the basal
level of histone acetylation and transcription of the TSHa gene in
the absence of any treatment (Figures 3 and 7). In the presence of
T3, this complex dissociates from the promoter resulting in
increased H3 acetylation whereas in the presence of cAMP, it
remains bound to the TSHa promoter. pCREB then recruits co-
activators with HAT activity, leading to both increased H4
acetylation and transcriptional activity. When cells are treated
with both T3 and cAMP, NCoR/HDAC3 complex dissociates
while co-activators remain bound to the promoter leading to an
intermediate level of transcriptional activity (Figures 1, 3, and 7).
These findings show that pCREB binding to CREs and the
resultant transcriptional activation is independent from TR
complex binding to TREs even though T3 can oppose cAMP
transactivation as previously reported [29]. Third, although CBP/
p300 and PCAF (Figures 3) are not involved in the negative
regulation of TSHa gene, it is possible that there may be another
co-factor mediating the H3 acetylation involved in negative
regulation. Additionally, this putative co-factor would be expected
to preferentially induce H3 acetylation on the TSHa promoter.
Previously, we showed that the increased histone acetylation by T3
does not significantly involve SRCs, p300, CBP or RIP140 [23],
lending further support for the possibility that another co-factor
with histone acetyltransferase activity (which does not recruit CBP,
p300, or PCAF) may participate in the negative regulation of
TSHa gene expression.
Our current and previous findings also show that an overall
increase in acetylation of H3 leads to negative regulation of the
TSHa promoter [23] whereas an increase in acetylation of H4
leads to transcriptional activation. However, when there is
concurrent H3 and H4 acetylation, as in the presence of T3 and
cAMP, negative regulation still occurs albeit at higher transcrip-
tional levels. Thus, when both signals act on the TSHa gene, H4
acetylation does not prevent H3 modifications and their
transcriptional consequences from occurring (i.e., negative regula-
tion) (Figures 2 and 7). Interestingly, an increase in acetylation
does not occur at all H3 acetylation sites. T3 causes an increase in
acetylation of H3K9 and H3K18 but does not affect acetylation of
H3K14 (Figure 3). Furthermore, in contrast to H3K9 and H3K18,
H3K27 acetylation is decreased by T3. It is not known how
H3K27 is de-acetylated after T3 treatment. It is possible that
another histone deacetylase can be recruited with T3 treatment
that acts preferentially at this site. It also is possible that the release
of HDAC3 from the promoter after T3 treatment may enable it to
act on H3K27 and reduce acetylation at that site. Of note, the
anti-H3 antibody used in Figure 2 does not detect H3K27
acetylation (Edward Lusby, Millipore Biosciences Division,
Figure 2. T3 and cAMP regulation of TSHa promoter activity and histone acetylation. A) T3 and cAMP regulation of TSHa promoter
activity. a-23 cells were treated 24 hours with no hormone/cAMP (control), 0.1 mMT 3, 1 mM dbcAMP, or both. The cell lysates were prepared and
luciferase activities were measured as described in Materials and Methods. B) Acute T3 and cAMP regulation of TSHa promoter activity. Luciferase
mRNA expression was analyzed by RT-PCR in cells treated for one hour with no hormone/cAMP (control), 0.1 mMT 3, 1 mM dbcAMP, or both. b-actin
gene expression was used for normalization. Shown in A and B are the mean of triplicate samples 6 SD. normalized to control as 100%. Similar
findings were found in two other experiments. **, p,0.05; *, p,0.01 difference from control using ANOVA analyses. C) T3 and cAMP regulation of
histone H3 and H4 acetylation. ChIP assay was performed as described in Materials and Methods using antibodies against acetylated H3 or H4. Similar
findings were observed in two other experiments. Note: ‘‘- ’’ indicates no hormone or cAMP treatment. D) Quantitative RT-PCR analyses of PCR
products from three separate ChIP experiments. The statistical analysis was performed utilizing ANOVA. Values are expressed as the mean 6 SD.
*, P,0.05 difference from control.
doi:10.1371/journal.pone.0009853.g002
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intriguing possibility that net H3 acetylation might be increased
after T3 treatment while acetylation at specific sites still can be
decreased. H3K27 acetylation is associated with transcriptional
activation [25,26] so its deacetylation combined with increased
H3K27 trimethylation would be expected to lead to decreased
transcriptional activity. Thus, it is not known whether the net
increase in histone H3 acetylation and/or a dominant effect by the
deacetylation/methylation of H3K27 plays a major role in the
negative regulation of the TSHa gene. Our data also showed that
acetylation of H4K5 and H4K8 participate in H4 acetylation by
cAMP. These sites previously have been reported to be associated
with CBP/p300/pCAF HAT activity [25,26].
We observed changes in methylation on different histones of the
TSHa promoter by T3 and cAMP. In the presence of T3, there
was a decrease in H3K9, and an increase in H3K27, trimethyla-
tion. These methylations were reciprocal to the histone acetylation
changes at these sites. Of note, H3K27 trimethylation previously
has been associated with transcriptional repression [25,26].
Additionally, H3K4 trimethylation increased in response to T3.
H3K4 trimethylation is generally associated with transcriptional
activation [25,26]; however, ligand-induced H3K4 demethylation
has been reported for nuclear hormone receptors, including TRs
[9–12] and associated with recruitment of the demethylase, LSD-
1. In this connection, it recently has been demonstrated that
approximately 10% of target genes containing H3K4 trimethyla-
tion also had H3K27 trimethylation, and most bivalent genes had
decreased transcription compared to those with H3K4 trimethyla-
tion alone [30]. As was the case for histone H3 acetylation, cAMP
did not affect the trimethylation of these H3 sites either in the
absence or presence of T3. In the presence of cAMP, H4K20
trimethylation decreased. Methylation at this site has been
reported previously to be associated with transcriptional repression
[25,26] so concomitant demethylation of H4K20 and acetylation
of H4K4 and H4K8 may contribute to the transcriptional
activation of TSHa gene by cAMP.
While negative and positive regulation of TSHa gene
expression by T3 and cAMP are due to changes localized to
specific histones, this is not necessarily the case for other target
genes. We have observed both H3 and H4 acetylations in T3-
mediated transcriptional activation of several endogenous target
genes in a-23 cells such as growth hormone, cyp7, PEPCK, and
SERRCA [23]; Wang and Yen, unpublished results). In particular,
we have observed H3K9 and H4K16 acetylation in these target
genes. Moreover, the acetylation of certain sites involved in the
negative regulation of TSHa (e.g., H3K9), also commonly occurs
in the positive regulation of these and other target genes by T3
[10]. Our findings thus suggest that individual target genes may
employ unique sets of histone marks to mediate either positive or
negative regulation.
In the clinical syndrome of RTH, patients typically have
elevated circulating thyroid hormone levels (T3 and T4) with
inappropriately normal or elevated serum TSH levels. The latter
occurs due to the lack of negative feedback control by thyroid
hormones on the expression of TSHa and TSHb subunits in
pituitary thyrotropes. This dysregulation in TSH secretion occurs
at the transcriptional level and is frequently due to expression of a
mutant TRb which has dominant negative activity on the
transcriptional activity of wild-type TRs. In our studies, a-23 cells
transformed with adenovirus that expressed the mutant TRb from
a patient with RTH, Mf-1, showed diminished negative regulation
of TSHa gene expression in the presence of T3. Mf-1 also
significantly blocked the increases in histone acetylation at H3K9
and H3K18 and the decrease in histone acetylation at H3K27
(Figure 6) as well as overall histone H3 acetylation (Wang and Yen,
unpublished results). Additionally, Mf-1 partially blocked the
decrease in H3K9 methylation and increases in H3K4 and
H3K27 methylation. Thus, Mf-1 blocked each of the previously
characterized H3 modifications induced by T3. It is likely that
some or all of these alterations in T3-induced changes in
chromatin structure may account for Mf-1’s dominant negative
activity on TSHa transcription and the loss of negative feedback
control of TSH by T3 seen in RTH patients (Figures 6 and 7).
With regard to positive regulation, we also have observed that Mf-
1 is able to block key histone modifications (e.g., H3K9Ac and
H3K4Me3) in several positively-regulated endogenous target
genes in a-23 cells (Wang and Yen, unpublished results). These
findings suggest that disruption of T3-dependent histone modifi-
cations by dominant negative mutant TRs may account for the
abnormalities in target gene expression observed in RTH patients.
In summary, we have shown that negative and positive
regulation of the TSHa gene involves histone type- and histone
site-specific modifications. Moreover, these histone modifications
were different for positive regulation by cAMP than for negative
regulation by T3. Thus, it appears that these independent and
non-overlapping modifications enable T3 to negatively regulate
TSHa gene expression and cAMP to mediate an increase in basal
transcription level. TRH stimulates intracellular cAMP concen-
tration and activates TSHa gene expression via pCREB binding to
the CREs located in the proximal promoter region [24,31]. Thus,
the persistent negative regulation of TSHa gene in a-23 cells in the
face of cAMP-mediated stimulation may explain the clinical
observation of a rapid decrease in TSH levels after acute T3
administration in hypothyroid patients [32]. Moreover, our
findings with Mf-1 suggest that the mechanism for inappropriate
TSH secretion in patients with RTH is likely due to blockade of
key histone modifications normally induced by thyroid hormone
on the TSHa subunit promoter. Our studies highlight some of the
key similarities and differences in co-factor recruitment and
histone modification that occur during the negative and positive
regulation of a target gene. They also demonstrate how opposing
hormonal and intracellular signals can be integrated via histone
modifications that determine chromatin structure and transcrip-
tional activity of the promoter.
Last, our studies demonstrate some of the difficulties in
interpreting and predicting transcriptional responses based upon
individual histone modifications; and thus, suggest that an
examination of a set of modifications on a given target gene, as
performed herein, will be more informative. It will be interesting
and worthwhile to see whether similar epigenetic changes for
positive and negative regulation occur on a genome-wide basis in
other target genes regulated by TRs, other nuclear hormone
Figure 3. Cofactor binding to TSHa promoter with cAMP and T3 treatment. Corepressor complex and coactivator binding to TSHa promoter
in the absence and presence of T3 cAMP. a-23 cells were treated for one hour with-/+ 0.1 mM T3 and -/+ 1 mM cAMP and harvested as in Figure 1C
and D. ChIP assays were performed similar to Figure 1C. Antibodies used in ChIP assay are indicated in Figure and described in Materials and
Methods. A) T3 and cAMP regulation of cofactor binding to the TSHa promoter. ChIP assay was performed as described in Materials and Methods
using antibodies against indicated co-factors. Similar findings were observed in two other experiments. Note: ‘‘- ’’ indicates no hormone or cAMP
treatment. B) Quantitative RT-PCR analyses of PCR products from three separate ChIP experiments using same antibodies as in Figure 3A (n=3). The
statistical analysis was performed utilizing ANOVA. Values are expressed as the mean 6 SD. *, P,0.05 difference from control.
doi:10.1371/journal.pone.0009853.g003
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pathways. Additionally, it is expected that disruption of histone
modifications of target genes by aberrant hormonal and
intracellular signals will be involved in the pathogenesis of other
endocrine and metabolic diseases.
Materials and Methods
Reagents
Dibutyryl cyclic AMP (dbcAMP) and triodothyronine were
purchased from Sigma–Aldrich, St. Louis, MO. Adenovirus
expressing wild-type TRb and dominant negative mutant TRb
(Mf-1) have been described previously [28,33]. a-23 cells were
generated from rat pituitary GH3 cells permanently-transfected
with human TSHa promoter spanning 2846 to +1 kindly
provided by Dr. Larry Jameson (Northwestern University) [19,23].
Antibodies
Antibody against acetyl-Histone3 and 4(AcH3, AcH4) were
purchased from Upstate Biotechnology/Millipore (06-599, 06-
866). Other histone acetylation and methylation antibodies were
purchased from Abcam, Cambridge, UK and include antibodies
against: histone acetyl H3K9 (ab4441), acetyl H3K27 (ab4729),
acetyl H3K18 (ab1191), tri-methyl H3K4 (ab8580), tri-methyl
H3K27 (ab6002), tri-methyl H3K9 (ab8898), tri-methyl H4K20
(ab9053), acetyl H4K5 (ab51997), acetyl H4K8 (ab15823), and
acetyl H4K16 (ab23352). Antibodies against NCoR(C-20),
SMRT(C-19), HDAC3(H-99), PCAF (E-8), p300 (C-20),CBP (A-
22), TR(C-1) were obtained from Santa Cruz Biotechnology,
Santa Cruz, CA. Anti-phospho-histone H3 (Ser10) was purchased
from Millipore, Billerica, MA. Anti-CREB antibody was pur-
chased from Cell Signaling Technology, Danvers, MA.
Cell culture, transient transfection, and reporter analyses
Monolayer cultures of clone a-2 3c e l l sw e r eg r o w ni nD u l b e c c o ’ s
modified Eagle’s medium (LifeTechnologies, Carlsbad, CA) supple-
mented with 10% heatedinactivated fetal calf serum (Biofluids,
Rockville,MD) and maintained in 5% CO2 atmosphere at 37uC.
Cells were transfected with 300 ng DNA/well in 12-well plates with
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Cell culture media was changed 6 hours
after transfection to antibiotic-free DMEM plus 10% charcoal-dextran
treated fetal bovine serum. After 48 hours, 10
27 MT 3 or 1 mM
dbcAMP in fresh media were added to the cells, and cells were
harvested, lysed and assayed for reporter gene activity the next day (16
hours later) using dual luciferase assay reagents according to the
manufacturer’s instructions (Promega, Madison, WI).
Adenoviral infection
293-HEK cells were transformed with adenoviruses expressing
wild-type TRb or dominant negative mutant Mf-1 [34]. Cell
lysates were obtained after 5 days, and then were added to 293
cells again. When most of the cells were killed by the adenovirus
infection and had detached, cell lysates were obtained again. This
process was repeated three times. Control adenovirus expressing
green fluorescent protein (Ad-GFP) was prepared in the same
manner. The adenovirus preparations then were purified and
concentrated by CsCl2 gradient ultracentrifugation two times.
After determining viral titres, a-23 cells (400,000 per 35-mm well)
were plated in culture media for two days, then washed twice with
PBS, and infected with adenovirus at a concentration of 50 viral
particles per cell in 0.5 ml of culture medium. One hour later, 1.5
ml of fresh culture medium was added to the cells which then were
allowed to grow for 24 hours before treatment with -/+ 10
27 MT 3
for one hour. Cells then were harvested, their RNA extracted, and
quantitative RT-PCR performed.
mRNA measurement quantitative RT-PCR
Total RNA was isolated from a-23 cells using TRIzol reagent
(Invitrogen, Carlsbad, CA). cDNAs were synthesized using random
primers and MultiScribeTM reverse transcriptase (Applied Biosystems,
Foster, CA). qRT-PCR was performed using SYBR Green Master
Mix (Applied Biosystems, Foster, CA) and Applied Biosystems 7300
sequence detector. The following qRT-PCR oligonucleotide primers
sets were used: Luciferase 59-CCAGGGATTTCAGTCGATGT-39
and the reverse primer 59-AATCTGACGCAGGCAGTTCT-39;r a t
beta-actin, forward, 59-CGCCGTTCCGAAATTGC 39, reverse 59-
GCCGCCGGGTTTTATAGG 39.0 . 5mM primers were used in the
PCRs [23].
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as previously described [7]. Briefly, a-
23 cells were grown to 90% confluence in phenol red-free
Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% charcoal DEXTRAN-stripped FBS for at least 3 days. After
additionof 10
27 MT 3 or 1 mMdbcAMPfor one hour, ChIP assays
were performed according to manufacturer’s protocol (Upstate
Biotechnology, Lake Placid, NY) with some minor modifications.
Briefly, chromatin was cross-linked in 1% formaldehyde in
phosphate buffered saline (PBS), and nuclei were extracted.
Chromatin was sonicated to yield 500- to 1,000-bp DNA fragments
and the supernatant containing precleared chromatin was then
incubated at 0uC overnight with different antibodies or rabbit IgG
control. After reverse cross-linking by heating the samples at 65uC
overnight, and treating with Proteinase K. DNA was purified using
Qiagen PCR Purification Kit per manufacturer’s instructions. PCR
was performed to visualize the enriched DNA fragments.using
primers which amplify the promoter region of TSHa in pGL2/
TSHa plasmid and part of the luciferase cDNA (Figure 1) [22].
Primers used were: 59CAGGATGTTATGTGTATGGCTC39 for
the TSHa promoter and 59CTTTATGTTTTTGGCGTCTTC39
for the luciferase gene. The upstream primer started at -324 bp and
the downstream primer started at +23 bp from transcriptional start
site of luciferase gene. Conventional PCR signals were stained with
ethidium bromide in 2% agarose gels.
Quantitative analyses of DNA products obtained from ChIP
assay were performed by RT-PCR with primers specific for the
human TSHa promoter [22]. RT-PCRs conducted on DNA
derived from input chromatin templates served as positive controls
whereas reactions conducted on IgG-precipitated templates served
as negative controls. In addition, we performed RT-PCRs using
primers to human TSHa promoter sequences to which TR and
other co-factors do not bind as well as to internal luciferase cDNA
sequences. The RT-PCR signal was barely detectable for these
Figure 4. Specific histone H3 modifications on TSHa promoter with cAMP and T3 treatment. a-23 cells were treated for one hour with no
hormone/cAMP, 0.1 mMT 3, 1mM cAMP or both before harvest and ChIP assay. A) Specific histone H3 modifications. Shown are bands from gel
electrophoresis of PCR products from ChIP assay using indicated anti-acetylated and anti-methylated H3 antibodies as indicated in the Figure. Similar
findings were observed in two other experiments. B) Quantitative RT-PCR analyses of PCR products from three separate ChIP experiments using same
antibodies as in Figure 4A (n=3). Statistical analyses performed as in Figure 1. *, p,0.05.
doi:10.1371/journal.pone.0009853.g004
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9853Figure 5. Specific histone H4 modifications on TSHa promoter with cAMP and T3 treatment. a-23 cells were treated for one hour with no
hormone/cAMP, 0.1 mMT 3, 1 mM cAMP or both before harvest and ChIP assay. A) Specific histone H4 modifications. Shown are bands from gel
electrophoresis of PCR products from ChIP assay using indicated anti-acetylated and anti-methylated H4 antibodies as indicated in the Figure. Similar
findings were observed in two other experiments. B) Quantitative RT-PCR analyses of PCR products from three separate ChIP experiments using same
antibodies as in Figure 5A (n=3). Statistical analyses performed as in Figure 1. *, p,0.05.
doi:10.1371/journal.pone.0009853.g005
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PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9853Figure 6. T3 effects on TSHa promoter activity and histone H3 modifications in a-23 cells overexpressed with wild-type TRb and
dominant negative mutant Mf-1. A) TSHa promoter activity in a-23 cells transformed with adenovirus green fluorescent protein (Ad-GFP),
adenovirus TRb (Ad-TRb) and adenovirus Mf-1. a-23 cells were plated in 12 well plates and cultured in charcoal-stripped 10% FBS-DMEM for three
days. Cells were transformed with adenovirus TRb or Mf-1 on the fourth day. On the fifth day, cells were treated for 1 hr -/+ 0.1 mMT 3 before harvest
and measurement of luciferase mRNA expression by quantitative RT-PCR. B) Histone H3 modifications on TSHa promoter in a-23 cells transformed
with adenovirus expressing GRP, TRb, or Mf-1. a-23 cells transformed with adenovirus GFP, TRb, or Mf-1 were treated for 1 hour with 2/+ 0.1 mMT 3
before harvest and ChIP assay. Shown are quantitative RT-PCR analyses of PCR products from using antibodies directed against specific H3
modifications as indicated in the Figure (n=3 experiments). Statistical analyses performed as in Figure 1. **, p,0.05; *, p,0.01 from untreated and
treated controls, respectively using ANOVA analyses.
doi:10.1371/journal.pone.0009853.g006
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PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9853controls. The signal for these samples and IgG-precipitated
templates was negligible on gels (Figure 5 and data not shown).
Relative amounts of immunoprecipitated co-factors or modified
histones (mean 6 S.D.) in ChIP assays are shown on the Y axes of
Figures 2D,3B, 4B, 5B, and 6B and determined from quantitative
qRT-PCR data using SYBR Green Master Mix (Applied
Biosystems, Foster, CA) and Applied Biosystems 7300 sequence
detector. Fluorescence from IgG precipitated samples was
subtracted from fluorescence from samples. Threshold cycles (Ct)
then were determined for ChIP samples and the input DNA, and
the relative amount of immunoprecipitated DNA (% ChIP signal
per input DNA) was calculated as 10062
DCt.
Statistical Analysis
The statistical analysis was performed utilizing an analysis of
variance (ANOVA). Values are expressed as the mean 6 standard
deviation of the mean (SD). The significance of differences
between the mean values was evaluated using the paired Student’s
t-test.
Acknowledgments
The authors also thank Drs. Rohit Sinha, Chui Sun Yap, and Jin Zhou
(Duke-NUS) for their critical reading of the manuscript and suggestions.
Author Contributions
Conceived and designed the experiments: DW XX PMY. Performed the
experiments: DW XX. Analyzed the data: DW XX REW SR PMY.
Contributed reagents/materials/analysis tools: DW XX REW SR PMY.
Wrote the paper: DW PMY.
References
1. Zhang J, Lazar MA (2000) The mechanism of action of thyroid hormones. Annu
Rev Physiol 62: 439–466.
2. Yen PM (2001) Physiological and molecular basis of thyroid hormone action.
Physiol Rev 81: 1097–1142.
3. Tomita A, Buchholz DR, Shi YB (2004) Recruitment of N-CoR/SMRT-
TBLR1 corepressor complex by unliganded thyroid hormone receptor for gene
repression during frog development. Mol Cell Biol 24: 3337–3346.
4. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, et al. (2003) Purification and
functional characterization of the human N-CoR complex: the roles of HDAC3,
TBL1 and TBLR1. EMBO J 22: 1336–1346.
5. Ishizuka T, Lazar MA (2003) The N-CoR/histone deacetylase 3 complex is
required for repression by thyroid hormone receptor. Mol Cell Biol 23:
5122–5131.
6. Sharma D, Fondell JD (2002) Ordered recruitment of histone acetyltransferases
and the TRAP/Mediator complex to thyroid hormone-responsive promoters in
vivo. Proc Natl Acad Sci U S A 99: 7934–7939.
7. Liu Y, Xia X, Fondell JD, Yen PM (2006) Thyroid hormone-regulated target
genes have distinct patterns of coactivator recruitment and histone acetylation.
Mol Endocrinol 20: 483–490.
8. Lee KC, Li J, Cole PA, Wong J, Kraus WL (2003) Transcriptional activation by
thyroid hormone receptor-beta involves chromatin remodeling, histone
acetylation, and synergistic stimulation by p300 and steroid receptor
coactivators. Mol Endocrinol 17: 908–922.
9. Ma H, Baumann CT, Li H, Strahl BD, Rice R, et al. (2001) Hormone-
dependent, CARM1-directed, arginine-specific methylation of histone H3 on a
steroid-regulated promoter. Curr Biol 11: 1981–1985.
10. Li J, Lin Q, Yoon HG, Huang ZQ, Strahl BD, et al. (2002) Involvement of
histone methylation and phosphorylation in regulation of transcription by
thyroid hormone receptor. Mol Cell Biol 22: 5688–5697.
11. Lonard DM, O’Malley BW (2005) Expanding functional diversity of the
coactivators. Trends Biochem Sci 30: 126–132.
12. Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, et al. (2007)
Histone methylation-dependent mechanisms impose ligand dependency for gene
activation by nuclear receptors. Cell 128: 505–518.
13. Lemon B, Inouye C, King DS, Tjian R (2001) Selectivity of chromatin-
remodelling cofactors for ligand-activated transcription. Nature 414:
924–928.
1 4 . Y a nZ ,C u iK ,M u r r a yD M ,L i n gC ,X u eY ,e ta l .( 2 0 0 5 )P B A Fc h r o m a t i n -
remodeling complex requires a novel specificity subunit, BAF200, to regulate
expression of selective interferon-responsive genes. Genes Dev 19:
1662–1667.
15. Rachez C, Freedman LP (2001) Mediator complexes and transcription. Curr
Opin Cell Biol 13: 274–280.
16. Park SW, Li G, Lin YP, Barrero MJ, Ge K, et al. (2005) Thyroid hormone-
induced juxtaposition of regulatory elements/factors and chromatin remodeling
of Crabp1 dependent on MED1/TRAP220. Mol Cell 19: 643–653.
Figure 7. Diagram of effects of cAMP and T3 on transcription of TSHa gene. Upper boxes denote histone and histone-modifying enzyme
changes associated with each treatment condition and transcriptional state. In RTH, histone modifications associated with negative regulation are
partially blocked.
doi:10.1371/journal.pone.0009853.g007
Histone Changes by T3 and cAMP
PLoS ONE | www.plosone.org 11 March 2010 | Volume 5 | Issue 3 | e985317. Feng X, Jiang Y, Meltzer P, Yen PM (2000) Thyroid hormone regulation of
hepatic genes in vivo detected by complementary DNA microarray. Mol
Endocrinol 14: 947–955.
18. Hollenberg AN, Monden T, Wondisford FE (1995) Ligand-independent and -
dependent functions of thyroid hormone receptor isoforms depend upon on their
distinct amino terminal. Journal of Biological Chemistry 270: 14272–14280.
19. Chatterjee VK, Lee JK, Rentoumis A, Jameson JL (1989) Negative regulation of
the thyroid-stimulating hormone alpha gene by thyroid hormone: receptor
interaction adjacent to the TATA box. Proc Natl Acad Sci U S A 86:
9114–9118.
20. Bodenner DL, Mroczynski MA, Weintraub BD, Radovick S, Wondisford FE
(1991) A detailed functional and structural analysis of a major thyroid hormone
inhibitory element in the human thyrotropin beta-subunit gene. J Biol Chem
266: 21666–21673.
21. Tagami T, Madison LD, Nagaya T, Jameson JL (1997) Nuclear receptor
corepressors activate rather than suppress basal transcription of genes that are
negatively regulated by thyroid hormone. Mol Cell Biol 17: 2642–2648.
22. Tagami T, Park Y, Jameson JL (1999) Mechanisms that mediate negative
regulation of the thyroid-stimulating hormone alpha gene by the thyroid
hormone receptor. J Biol Chem 274: 22345–22353.
23. Wang D, Xia X, Liu Y Oetting A, Walker RL, et al. (2009) Negative regulation
of TSHalpha target gene by thyroid hormone involves histone acetylation and
corepressor complex dissociation. Mol Endocrinol 23: 600–609. Epub 2009 Feb
2005.
24. Hashimoto K, Zanger L, Hollenberg AN, Cohen LE, Radovick S, et al. (2000)
cAMP response element-binding protein-binding protein mediates thyrotropin-
releasing hormone signaling on thyrotropin subunit genes. J Biol Chem 275:
33365–33372.
25. Berger S (2002) Histone modifications in transcriptional regulation. Curr Opin
Genet Dev 12: 142–148.
26. Jenuwein T, Allis C (2001) Translating the histone code. Science 293:
1074–1080.
27. Yen PM (2003) Molecular basis of resistance to thyroid hormone. Trends
Endocrinol Metab 14: 327–333.
28. Sakurai A, Takeda K, Ain K, Ceccarelli P, Nakai A, et al. (1989) Generalized
resistance to thyroid hormone associated with a mutation in the ligand-binding
domain of the human thyroid hormone receptor b. Proc Natl Acad Sci USA 86:
8977–8981.
29. Mendez-Pertu M, Sanchez-Pacheco A, Aranda A (2003) The thyroid hormone
receptor antagonizes CREB-mediated transcription. Embo J 22: 3102–3112.
30. Zhao XD, Han X, Chew JL, Liu J, Chiu KP, et al. (2007) Whole-genome
mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic
compartments in human embryonic stem cells. Cell Stem Cell 1: 286–298.
31. Kim DS, Ahn SK, Yoon JH, Hong SH, Kim KE, et al. (1994) Involvement of a
cAMP-responsive DNA element in mediating TRH responsiveness of the human
thyrotropin alpha-subunit gene. Mol Endocrinol 8: 528–536.
32. Ladenson PW, Goldenheim PD, Ridgway EC (1983) Rapid pituitary and
peripheral tissue responses to intravenous L-triiodothyronine in hypothyroidism.
J Clin Endocrinol Metab 56: 1252–1259.
33. Hayashi Y, Depaoli AM, Burant CF, Refetoff S (1994) Expression of a thyroid
hormone-responsive recombinant gene introduced into adult mice livers by
replication-defective adenovirus can be regulated by endogenous thyroid
hormne receptor. Journal of Biological Chemistry 269: 23872–23875.
34. Hayashi Y, Mangoura D, Refetoff S (1996) A mouse model of resistance to
thyroid hormone produced by somatic gene transfer of a mutant thyroid
hormone receptor. Mol Endocrinol 10: 100–106.
Histone Changes by T3 and cAMP
PLoS ONE | www.plosone.org 12 March 2010 | Volume 5 | Issue 3 | e9853